Student or educator? Sign up with your school email and get 6 months of Pro free.
CoChat
Cited by 164

The DOI matches its Crossref record; 1 of the 1 references it cites were found in a registry or an index.

Safety and Efficacy of Nivolumab in Brain Metastases From Renal Cell Carcinoma: Results of the GETUG-AFU 26 NIVOREN Multicenter Phase II Study

Flippot, Ronan, Dalban, Cécile, Laguerre, Brigitte, Borchiellini, Delphine, Gravis, Gwénaelle, Négrier, Sylvie, Chevreau, Christine, Joly, Florence, Geoffrois, Lionnel, Ladoire, Sylvain, Mahammedi, Hakim, Rolland, Frédéric, Gross-Goupil, Marine, Deluche, Elise, Priou, Frank, Laramas, Mathieu, Barthélémy, Philippe, Narciso, Bérengère, Houedé, Nadine, Culine, Stéphane, Oudard, Stéphane, Chenot, Marina, Tantot, Florence, Chabaud, Sylvie, Escudier, Bernard, Albiges, Laurence · 2019 · Journal of Clinical Oncology

Abstract

PURPOSE: Nivolumab is standard of care for patients with metastatic clear cell renal cell carcinoma (ccRCC) after failure of antiangiogenic therapies, but its activity on brain metastases from ccRCC remains unknown, because these patients were excluded from pivotal studies. We aimed to assess the activity of nivolumab in this population. METHODS: The GETUG-AFU 26 NIVOREN phase II trial assessed the activity and safety of nivolumab in patients with metastatic ccRCC who failed vascular endothelial growth factor–directed therapies ( ClinicalTrials.gov identifier: NCT03013335 ). Patients with asymptomatic brain metastases were prospectively identified and underwent dedicated brain evaluation. Two cohorts were constituted: cohort A comprised patients with previously untreated brain metastases, and cohort B comprised patients whose brain metastases underwent prior therapy. The primary end point was intracranial response rate in cohort A. RESULTS: Seventy-three patients with brain metastases were included: 39 in cohort A and 34 in cohort B. Intracranial response rate was 12% in cohort A; no objective response was reported in patients with brain lesions that were multiple or larger than 1 cm. Median intracranial progression-free survival was 2.7 months (95% CI, 2.3 to 4.6 months) in cohort A and 4.8 months (95% CI, 3.0 to 8.0 months) in cohort B, with adjusted hazard ratio of 2.04 (95% CI, 1.08 to 3.83). Overall survival rate at 12 months was 67% (95% CI, 49.6% to 79.1%) in cohort A and 59% (95% CI, 40.6% to 73.2%) in cohort B. Most patients in cohort A (72%) needed subsequent focal brain therapy. Nivolumab was well tolerated, with no unexpected toxicity. CONCLUSION: Nivolumab activity is limited in patients with untreated brain metastases from ccRCC. Brain imaging and focal therapy should be considered before immune checkpoint inhibitors in patients with metastatic ccRCC.

Overview

The claims and statistics of this paper haven’t been checked yet.

Free: it reads the open-access text and checks the first 5 claims that cite a source we can check. Create a free account to check every claim.

A few free checks a day · papers already verified open instantly · results are public

Integrity signals

Registry

Crossref · 10.1200/jco.18.02218

Cites

1 of 1 references verified0 citation errors · 0 not checkable

Statistics

Verification

Claims the paper makes

The claims and statistics of this paper haven’t been checked yet.

Free: it reads the open-access text and checks the first 5 claims that cite a source we can check. Create a free account to check every claim.

A few free checks a day · papers already verified open instantly · results are public

Self-check

Percentages, sums and reported differences re-computed from the paper’s own numbers.

The self-check needs the paper’s full text.

Citations

Cites

Show all 1 references

Cited by

See all 164

Metadata

Authors
Flippot, R., Dalban, C., Laguerre, B., Borchiellini, D., Gravis, G., Négrier, S., Chevreau, C., Joly, F., Geoffrois, L., Ladoire, S., Mahammedi, H., Rolland, F., Gross-Goupil, M., Deluche, E., Priou, F., Laramas, M., Barthélémy, P., Narciso, B., Houedé, N., Culine, S., Oudard, S., Chenot, M., Tantot, F., Chabaud, S., Escudier, B., & Albiges, L.
Venue
Journal of Clinical Oncology
Published
2019-08-10
Volume
37
Issue
23
Pages
2008-2016
ISSN
  • 0732-183X (ISSN-L)
  • 1527-7755
OpenAlex
W2950990372
Cited by
164
References
1
FWCI
16.31
Type
journal article
Language
en
Open access
closed

About these checks

Registry, retraction, Cites and statistics results are computed, not judged, with one exception: a printed reference that no index lists is read once by a model before it counts as a citation error. Claims are extracted by a model and kept only when their quote appears verbatim in the text; each cited source is then checked, with a model’s help, for whether it says what the claim relies on. Those verdicts can be wrong — read the claim’s quote and the cited source before relying on one.

Statistics and arithmetic are recomputed, not judged.

Confidence bands are shown only for fields calibrated on our annotated test set. None is calibrated yet, so no band is shown.

What counts as a claim ›How we measure confidence ›How we check this ›

Are you an author, or do you see a problem with this page? Request a review

How to cite

Cite CoChat for the checks on this page, and the paper for its own findings.

This page
CoChat. (2026). Citation check: Safety and Efficacy of Nivolumab in Brain Metastases From Renal Cell Carcinoma: Results of the GETUG-AFU 26 NIVOREN Multicenter Phase II Study. https://app.cochat.ai/papers/10.1200/jco.18.02218
The paper
Flippot, R., Dalban, C., Laguerre, B., Borchiellini, D., Gravis, G., Négrier, S., Chevreau, C., Joly, F., Geoffrois, L., Ladoire, S., Mahammedi, H., Rolland, F., Gross-Goupil, M., Deluche, E., Priou, F., Laramas, M., Barthélémy, P., Narciso, B., Houedé, N., . . . Albiges, L. (2019). Safety and Efficacy of Nivolumab in Brain Metastases From Renal Cell Carcinoma: Results of the GETUG-AFU 26 NIVOREN Multicenter Phase II Study. Journal of Clinical Oncology. https://doi.org/10.1200/jco.18.02218

Data sources

Bibliographic data: Semantic Scholar, OpenAlex, Crossref.

Contains information from the Semantic Scholar Academic Graph Datasets, made available under the ODC Attribution License (ODC-BY 1.0).

Semantic Scholar’s data is described in: Kinney, R., et al. (2023). The Semantic Scholar Open Data Platform. arXiv:2301.10140.